Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1B Study of the Safety of LAM561 Administered Orally in Combination With Temozolomide (TMZ) and Radiation Therapy or With TMZ Alone in the First Line Treatment of Subjects With Glioblastoma

NCT03867123 is registered in ClinicalTrials.gov with Laminar Pharmaceuticals as lead sponsor.

NCT NCT03867123
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03867123 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1B Study of the Safety of LAM561 Administered Orally in Combination With Temozolomide (TMZ) and Radiation Therapy or With TMZ Alone in the First Line Treatment of Subjects With Glioblastoma
Lead sponsor
Laminar Pharmaceuticals
Phase
Phase 1
Overall status
Completed
Start date
December 4, 2018
Completion date
July 1, 2020
Enrollment
18 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

glioblastoma (gbm)